Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...

詳細記述

保存先:
書誌詳細
主要な著者: Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., Maziarz, Richard T.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2008
主題:
Transplantation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/
https://ncbi.nlm.nih.gov/pubmed/18664621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料